Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

15 Jun 2015

Abstract excerpt

Triple-negative breast cancers (TNBC) lacking estrogen, progesterone, and HER2 receptors account for 10% to 20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecularly targeted approach to target aberrant epigenetics of TNBC using a peptide corresponding to the SIN3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Peptides and Activities
Share to Epigenetics and DNA Methylation
Share to Parasitic Diseases Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26078298
DOI: 10.1158/1535-7163.mct-14-0980-t

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerPMID 26078298Read ↗

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast CancerSemantic proximity Read ↗

Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b PathwaysSemantic proximity Read ↗

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancersSemantic proximity Read ↗

Synthesis and Evaluation of Naphthalene Derivatives as Potent STAT3 inhibitors and Agents Against Triple-Negative Breast Cancer Growth and MetastasisSemantic proximity Read ↗

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancersSemantic proximity Read ↗

Peptide molecular glues select between BET paralogues by exploiting allosteric sites and conformational dynamicsSemantic proximity Read ↗

Hydroxamic Acid and Benzoic Acid–Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In VivoSemantic proximity Read ↗

Selective targeting of epigenetic reader domainsSemantic proximity Read ↗

Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonistsSemantic proximity Read ↗

Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.Semantic proximity Read ↗

Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell featuresSemantic proximity Read ↗

The potential of Senicapoc, a KCNN4 inhibitor, for the prevention and treatment of breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.